Polycystic liver disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:23:52 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Polycystic liver disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the effectiveness and safety of ursodeoxycholic acid in patients with hepatorenal polycystic diseases. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-ursodeoxycholic-acid-in-patients-with-hepatorenal-polycystic-diseases/ Wed, 29 Apr 2026 15:09:13 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-ursodeoxycholic-acid-in-patients-with-hepatorenal-polycystic-diseases/ This study focuses on Hepatorenal polycystic diseases, which are conditions where fluid-filled sacs, known as cysts, grow in both the liver and the kidneys. The goal of the research is to evaluate the effectiveness and safety of ursodeoxycholic acid compared to a placebo in slowing the growth of these cysts in the liver.

During the study, participants will be monitored to see how the medication affects the size of the liver and kidney cysts, as well as overall organ function. This includes checking renal function, which refers to how well the kidneys filter waste from the blood, and monitoring liver profile markers through blood tests to ensure safety. Researchers will also look at genetic information and certain proteins or molecules in the blood, often called biomarkers, to better understand how the disease progresses and how individuals respond to the treatment.

]]> Study on Leuprorelin Acetate for Slowing Disease Progression in Premenopausal Women with Severe Polycystic Liver Disease https://clinicaltrials.eu/trial/study-on-leuprorelin-acetate-for-slowing-disease-progression-in-premenopausal-women-with-severe-polycystic-liver-disease/ Wed, 29 Apr 2026 15:02:03 +0000 https://clinicaltrials.eu/trial/study-on-leuprorelin-acetate-for-slowing-disease-progression-in-premenopausal-women-with-severe-polycystic-liver-disease/ This clinical trial is focused on studying polycystic liver disease, a condition where multiple cysts form in the liver, causing it to enlarge. The treatment being tested is called leuprorelin acetate, which is a medication that helps lower certain hormone levels in the body. The purpose of the study is to see if this treatment can slow down the growth of the liver in women who have this disease.

Participants in the study will be divided into two groups. One group will start receiving the treatment right away, while the other group will have a delayed start. The study will last for 18 months, during which the growth of the liver will be monitored using MRI scans. The study aims to compare the liver growth rates between the two groups to determine the effectiveness of the treatment.

Throughout the study, researchers will also keep track of any symptoms related to polycystic liver disease and any side effects that may occur. This information will help in understanding how the treatment affects the participants’ overall health and well-being. The study is designed to provide valuable insights into managing polycystic liver disease and improving treatment options for those affected by it.

]]> Study on Octreotide for Patients with Symptomatic Polycystic Liver Disease https://clinicaltrials.eu/trial/study-on-octreotide-for-patients-with-symptomatic-polycystic-liver-disease/ Wed, 29 Apr 2026 14:23:43 +0000 https://clinicaltrials.eu/trial/study-on-octreotide-for-patients-with-symptomatic-polycystic-liver-disease/ This clinical trial is focused on studying polycystic liver disease, a condition where multiple cysts form in the liver, leading to symptoms like bloating, abdominal discomfort, and pain. The trial will evaluate a treatment called CAM2029 (octreotide subcutaneous depot), which is administered as an injection under the skin. The purpose of the study is to assess the effectiveness and safety of this treatment in reducing liver volume in patients with this condition.

Participants in the trial will receive either the CAM2029 treatment or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This approach helps ensure unbiased results. The trial will take place over a period of time, with regular check-ups and assessments to monitor changes in liver size and symptoms.

Throughout the study, participants will undergo various evaluations, including MRI scans to measure liver volume and assessments of symptom changes. The trial aims to provide valuable information on how CAM2029 can potentially benefit those with polycystic liver disease, offering insights into its impact on liver size and overall health. Participants’ safety and well-being will be closely monitored throughout the trial period.

]]>